Dr. Mahadevan receives national award for cancer drug discovery targeting NHEJ DNA repair

Thursday, February 2, 2017

Daruka Mahadevan, MD, PhD, professor of Medicine, director of Phase I Program, co-director of Experimental Therapeutics and Maynard endowed chair at the University of Arizona Cancer Center, was named a 2017 recipient of the Harrington Scholar-Innovator Awards. The awards support breakthrough discoveries of Physician-Scientists whose research shows promise to advance the standard of care.

Dr. Mahadevan is a recognized structure-based expert in drug discovery and acclaimed drug developer in early phase therapeutic trials in Hematology and Oncology. His laboratory, in collaboration with assistant professor Eric Weterings, PhD, and associate research professor Josef Vagner, PhD, has discovered and developing a small molecule inhibitor to Ku70/80, a key protein in non-homologous end joining (NHEJ) DNA Repair. This is a new class of drugs that can sensitize cancer cells to current standard of care modalities including radiation therapy. As a Harrington Scholar, he will have access to several rounds of capital, up to a total of $700,000 to support the transition of his work into the private sector.

In addition to financial support, the Institute provides direction from leaders in the pharmaceutical industry who are charged with overseeing therapeutic development of Scholar programs.

Learn more about Dr. Mahadavan and his research program on his UA Cancer Center profile page.

Read The Harrington Institute announcement here.